Drugs / Resatorvid
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07092215 | Jun → Jul 2025 | — | Stefan Heber | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04620148 | Dec 2021 → Dec 2022 | liver disorder | Akaza Bioscience Ltd | Unknown | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT00633477 | Feb 2008 → Feb 2009 | infectious disease with sepsis | Takeda | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00143611 | Sep 2005 → Feb 2007 | infectious disease with sepsis | Takeda | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06890039 Comparator | Jun 2026 → Aug 2028 expected | alcoholic hepatitis, alcoholic liver cirrhosis | Yaqrit Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-05-07 | Yaqrit Ltd | Results EASL 2025 YAQ005 + YAQ007: Transcriptomic and metabolic insights into hyperammonemia yaqrit.com ↗
Ammonia levels were significantly elevated in WT-AA mice and both TAK-242 and OP treatment effectively reduced ammonia levels. |
| 2025-05-07 | Yaqrit Ltd | Results EASL 2025 YAQ005: Toll-like receptor 4 inhibition restores cytochrome C oxidase yaqrit.com ↗
Toll-like receptor 4 inhibition restores cytochrome C oxidase |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-07 | Yaqrit Ltd | EASL 2025 YAQ005 + YAQ007: Transcriptomic and metabolic insights into hyperammonemia yaqrit.com ↗ |
| 2025-05-07 | Yaqrit Ltd | EASL 2025 YAQ005: Toll-like receptor 4 inhibition restores cytochrome C oxidase yaqrit.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Resatorvid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00633477 ↗ |
| Known as | Cli-095 | ChEMBL registry synonym — accepted as the source's own label CHEMBL225157 ↗ |
| Known as | TAK-242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620148 ↗ |
| Action | Inhibit | “acts by inhibiting TLR-4 mediated signaling” NCT00143611 ↗ |
| Modality | Small molecule | “TAK-242 (resatorvid) is a small molecule suppressor of pathogen-induced release of inflammatory cytokines” NCT00143611 ↗ |
| Route | Subcutaneous | “injection, subcutaneously for thirty minutes” NCT00143611 ↗ |
| Target | TLR4 | “Resatorvid This TLR4 antagonist” NCT07092215 ↗ |